Actuate Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Actuate Therapeutics (ACTU).

Price Target Range — 5 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$14Upside to Avg. PT+4221.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 18, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$15
Jul 30, 2026	Rodman & Renshaw	Michael G. King Jr.	Initiate	Buy	$6
May 18, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$15
Apr 22, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$15
Apr 13, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$20→$15
Nov 19, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$20
Sep 23, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$20
Aug 26, 2025	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$20
Aug 18, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$20
Mar 17, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Initiate	Buy	$20

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.

Benzinga Newsdesk

This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.

Avi Kapoor

PRO
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.

Benzinga Newsdesk

Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.

Avi Kapoor

Actuate Therapeutics Inc

Actuate Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PRO
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday

People Also Watch

People Also Watch

Actuate Therapeutics Inc

Actuate Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PRORodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6

PROHC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

PROHC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

PRO
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target